Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IVX: IVAX Corporation -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (72)	10/24/2005 12:56:02 PM
From: Jim Oravetz	Read Replies (1) \| Respond to of 78

IVAX Sees 3Q EPS 20c/Shr,Including 4c/Shr From Merger Chgs DOW JONES NEWSWIRES October 24, 2005 8:34 a.m. MIAMI -- Ivax Corp. (IVX) expects third-quarter earnings of about 20 cents a share, including a charge of 4 cents a share from merger-related items. In a press release Monday, the generic pharmaceutical company said "we believe the current analysts' estimates do not take these items into account." Wall Street is predicting earnings of 23 cents a share, according to a survey of analysts by Thomson First Call. In the year-earlier quarter, the company earned 17 cents a share. In July Ivax announced it would be acquired by Israel-based generic-drug company Teva Pharmaceutical Industries Inc. (TEVA) for $7.3 billion. Ivax will announce third-quarter results on Nov. 8, and hold a conference call at 11 a.m. EDT that day. Company Web site: ivax.com